Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensity score‐matched study

Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensity score‐matched study

Abstract Objectives Our research aimed to evaluate the effectiveness of first‐line immune checkpoint inhibitors (ICIs) with etoposide and platinum (EP) for extensive‐stage small cell lung cancer (ES‐SCLC) and identify prognostic factors, as real‐world outcomes and the inconsistency of PD‐1 and PD‐L1...

Full description

Bibliographic Details
Main Authors: Jingyuan Xie, Mo Chen, Hedong Han, Ke Xu, Guihuan Qiu, Xinqing Lin, Yong Song, Jinjun Ye, Tangfeng Lv, Ping Zhan
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Thoracic Cancer
Subjects:
extensive‐stage SCLC
PD‐1 inhibitors
PD‐L1 inhibitors
propensity score‐matched analysis
risk factors
Online Access:https://doi.org/10.1111/1759-7714.14874

Internet

https://doi.org/10.1111/1759-7714.14874

Similar Items